Trials / Withdrawn
WithdrawnNCT04452643
Efficacy of BACMUNE (MV130) in the Prevention of Disease Due to COVID-19 Infection in Healthcare Personnel
Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial on the Efficacy of BACMUNE (MV130) in the Prevention of Disease Due to SARS-CoV-2 Infection in Healthcare Personnel
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Inmunotek S.L. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to assess the effect of immunotherapy with the bacterial preparation MV130 on the spread and course of SARS-CoV-2 infection in highly exposed subjets, as is the case with healthcare personnel.
Detailed description
This is a prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial to assess the efficacy of BACMUNE (MV130) in the prevention of disease due to SARS-VoC-2 infection in healthcare personnel
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | BACMUNE (MV130) | BACMUNE (MV130) is a bacterial preparation that contains a mixture of Gram + and Gram - inactivated bacteria at the concentration of 300 FTU / mL (approx. 10\^9 bacteria / mL) |
| OTHER | Placebo | Placebo is a solution on sodium chloride at 0.9% |
Timeline
- Start date
- 2020-10-01
- Primary completion
- 2021-12-01
- Completion
- 2021-12-01
- First posted
- 2020-06-30
- Last updated
- 2020-11-02
Locations
3 sites across 1 country: Mexico
Source: ClinicalTrials.gov record NCT04452643. Inclusion in this directory is not an endorsement.